Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Mabwell OK’d to Begin US Clinical Trials of ADC for Solid Tumors

publication date: Feb 21, 2024

Shanghai’s Mabwell was approved to start US clinical trials of its B7-H3 targeting ADC for advanced malignant solid tumors. The company describes 7MW3711 as a next-gen antibody-drug conjugate comprised of an innovative antibody molecule, novel linker and novel payload (topoisomerase I inhibitor) that was developed on its drug conjugate platform IDDC™. B7-H3 is overexpressed in most cancer types but expressed at a low level in normal tissues. In malignant tissues, B7-H3 inhibits tumor antigen-specific immune responses. The company has already started a 7MW3711 clinical trial in China. More details....

Stock Symbol: (SHA: 688062)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital